P972: INDIRECT COMPARISON OF TECLISTIMAB IN MAJESTEC-1 VERSUS PHYSICIAN'S CHOICE OF THERAPY IN LONG-TERM FOLLOW-UP OF TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA IN DARATUMUMAB TRIALS. (23rd June 2022) - Weisel, K.; Chari, A.; Usmani, S. Z.; Goldschmidt, H.; Mateos, M.-V.; Qi, K.; Londhe, A.; Nair, S.; Lin, X.; Pei, L.; Ammann, E.; Kobos, R.; et al.